Category: PMCPA Case of the Week

Cases selected for the AskAnzal weekly PMCPA insight newsletter

8 Mar 2026

AUTH/1962/2/07: PCT adviser v AstraZeneca – Symbicort budget impact model presented to practice managers (no breach)

A PCT adviser challenged AstraZeneca’s Symbicort budget impact presentation to GP practice managers and meeting sponsorship. Panel found…

8 Mar 2026

PMCPA AUTH/3006/12/17: Director v Lilly (Trulicity) – clinical trial disclosure

PMCPA case AUTH/3006/12/17 (Director v Lilly) concerning clinical trial disclosure for Trulicity. Outcome: No breach; matter was outwith…

8 Mar 2026

AUTH/3131/12/18: Anonymous (non-contactable) v Napp β€” social media meeting adverts and sponsorship disclosure (No breach)

Complaint alleged Facebook/Twitter meeting adverts lacked sponsorship statements and reached the public. Panel initially found a Clause 22.4…

8 Mar 2026

AUTH/2188/12/08: General Practitioner v Ashfield In2Focus (Conduct of a representative) – No breach (outwith scope)

PMCPA case AUTH/2188/12/08: complaint about conduct of a representative. The matter was ruled outwith the scope of the…

8 Mar 2026

AUTH/3250/10/19: Lilly/Director v Janssen – Tremfya (guselkumab) and psoriatic arthritis β€˜pipeline’ session ruled promotional (breach of undertaking)

Janssen’s BSR β€œPipelines in PsA” innovation theatre session was ruled not to be legitimate scientific exchange and to…

8 Mar 2026

Britannia Pharmaceuticals: β€œApo-go Pump” branding ruled misleading (AUTH/3377/9/20)

Employee complaint upheld after Britannia used β€œApo-go Pump” name/logo despite Apo-go not being supplied as a pump. Panel…

8 Mar 2026

AUTH/3442/12/20: Complainant v GlaxoSmithKline (LinkedIn pipeline trial posts) – No breach

Complaint alleged GSK promoted unlicensed RSV vaccine and Covid-19 antibody treatment to the public via LinkedIn. Panel ruled…

8 Mar 2026

AUTH/3560/9/21: Anonymous health professional complaint about pressure to sign up to diabetes review service (No breach) – Sanofi

Anonymous nurse alleged a Sanofi account executive pressured them to sign up to a diabetes therapy review service…

8 Mar 2026

AUTH/3482/3/21: Complainant v GlaxoSmithKline (LinkedIn post about Nucala) – Out of scope of the ABPI Code

A complaint alleged promotion of Nucala (mepolizumab) on LinkedIn. The PMCPA recorded the case as outwith the scope…

8 Mar 2026

Tetris Pharma: LinkedIn sponsored message for Ogluo reached a non-HCP (public promotion) and lacked required safety/INN elements

A LinkedIn sponsored message promoting Ogluo (glucagon) was received by a non-HCP. The Panel found public promotion plus…

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training